• Home
    • About Us
  • KRIYA Conference
  • Resources
    • Find a Provider
    • Reading List
    • Videos & Podcasts
    • Lectures
    • Articles
    • Books
    • Music
    • Hotlines
    • Low Fee Psychotherapy
  • For Clinicians
    • Guidelines
    • Trainings
    • Networking Events
    • Supply List
    • Forms
    • Clinical Scales
    • COVID
  • Contact Us
    • Mailing List
  • Site Map

KRIYA Ketamine Research Institute

Reading List

Here is a list of recommended readings about therapeutic ketamine, organized by topic. (This list will be updated periodically.) Please think of this list as a “tasting menu” of various important aspects of therapeutic ketamine treatment. For an exhaustive list of reference materials, please go to PubMed. On this website, you can also find a list of books about therapeutic ketamine, and articles that cite Dr. Bennett specifically.


ESSENTIAL READING

Bahji, A., Zarate, C. A., Vazquez, G. H. (2022). Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis. Expert Opin Drug Saf. (06/21/22). 853-866. DOI: 10.1080/14740338.2022.2047928
https://pubmed.ncbi.nlm.nih.gov/35231204/

Bennett, R. (2019). Paradigms of ketamine treatment. MAPS Bulletin, 29(1).
https://maps.org/news/bulletin/articles/436-maps-bulletin-spring-2019-vol-29,-no-1/7718-paradigms-of-ketamine-treatment-spring-2019

Sewell, A. (2007). Ketamine: Peril and promise. MAPS Bulletin, XVII (1). 
https://maps.org/news-letters/v17n1-html/ketamine-peril_and_promise.html

BACKGROUND & HISTORY

Domino, E. (1965). Taming the Ketamine Tiger. Republished in Anesthesiology (Sept 2010, vol 113), 678-684.
https://doi.org/10.1097/ALN.0b013e3181ed09a2

McIntyre, R. S., Rosenblat, J. D., Nemeroff, C. B., Sanacora, G., Murrough, J. M., … Zarate, C. A. (2021). Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: An international expert opinion on the available evidence and implementation. American Journal of Psychiatry (03/17/21).
doi.org/10.1176/appi.ajp.2020.20081251

Oaklander, M. (2017). New hope for depression. TIME.
https://time.com/magazine/us/4876068/august-7th-2017-vol-190-no-6-u-s/

Ryan, W. C., Marta, C. J., & Koek, R. J. (2014). Ketamine and depression: A review. International Journal of Transpersonal Studies, 33(2), 40–74. DOI: 10.24972/ijts.2014.33.2.40
http://dx.doi.org/10.24972/ijts.2014.33.2.40

Sanacora, G., Frye, M. A., McDonald, W., Mathew, S. J., Turner, M. S., Schatzberg, A. F., Summergrad, P., & Nemeroff, C. B. (2017). A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry, 74(4), 399-405. DOI: 10.1001/jamapsychiatry.2017.0080
https://adaa.org/sites/default/files/Ketamine%20JAMA%20Journal%20Article%20-%20Charlie%20Nemeroff.pdf

Thielking, M. (2018). Is the ketamine boom getting out of hand? Scientific American, 09/26/18.
https://www.scientificamerican.com/article/is-the-ketamine-boom-getting-out-of-hand/

DISSOCIATIVE & PSYCHEDELIC EXPERIENCE

Kolp, E., Friedman, H. L., Krupitsky, E., Jansen, K., Sylvester, M., Young, M. S., & Kolp, A. (2014). Ketamine psychedelic psychotherapy: Focus on its pharmacology, phenomenology, and clinical applications. International Journal of Transpersonal Studies, 33(2), 84-140.
https://doi.org/10.24972/ijts.2014.33.2.84

Krupitsky, E. M., & Grinenko, A. Y. (1997). Ketamine psychedelic therapy (KPT): A review of the results of ten years of research. Journal of psychoactive drugs, 29(2), 165-183.
https://doi.org/10.1080/02791072.1997.10400185

Kungurtsev, I. (1991). “Death-rebirth” psychotherapy with ketamine. The Albert Hoffman Foundation Bulletin. 
http://whale.to/b/kungurtsev.html

Luckenbaugh, D. A., Niciu, M. J., Ionescu, D. F., et al. (2014). Do the dissociative side effects of ketamine mediate its antidepressant effects? Journal of Affective Disorders, 159, 56-61.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4065787/

Mathai, D., Mathew, S. J., Storch, E. A., & Kosten, T. R. (2018). Revisiting the hallucinogenic potential of ketamine. Psychiatric Times, 35(6).
https://www.psychiatrictimes.com/view/revisiting-hallucinogenic-potential-ketamine

Mathai, D. S., Meyer, M. J., Storch, E. A., & Kosten, T. R. (2020). The relationship between subjective effects induced by a single dose of ketamine and treatment response in patients with major depressive disorder: A systematic review. Journal of Affective Disorders, 264, 123-129.
https://doi.org/10.1016/j.jad.2019.12.023

COMBINING KETAMINE WITH PSYCHOTHERAPY

Dore, J., Turnipseed, B., Dwyer, S., Turnipseed, A., Andries, J., Ascani, G., Monnette, C., Huidekoper, A., Strauss, N., & Wolfson, P. (2019). Ketamine assisted psychotherapy (KAP): Patient demographics, clinical data and outcomes in three large practices administering ketamine with psychotherapy, Journal of Psychoactive Drugs, 51(2), 189-198. DOI: 10.1080/02791072.2019.1587556
https://www.tandfonline.com/doi/full/10.1080/02791072.2019.1587556

Gold, V. & Sienknecht, E. (2020) Ketamine-assisted psychotherapy online? Psychedelic Support, 06/19/2020.
www.psychedelic.support/resources/ketamine-assisted-psychotherapy-online/

Greenway, K. T., Garel, N., Jerome, L. & Feduccia, A. (2020). Integrating psychotherapy and psychopharmacology: Psychedelic-assisted psychotherapy and other combined treatments. Expert Review of Clinical Pharmacology.
https://doi.org/10.1080/17512433.2020.1772054

Katzman, J. (2018). Rapid depression remission and the “therapeutic bends” with ketamine-assisted psychotherapy. Psychedelics Today.
https://www.healingrealmscenter.com/blog/rapid-depression-remission-and-the-therapeutic-bends

Kolp, E., Young, S. M., Freidman, H., Krupitsky, E., Jansen, K., & O’Connor, L. (2007). Ketamine-enhanced psychotherapy: Preliminary clinical observations on its effects in treating death anxiety. International Journal of Transpersonal Studies, 26(1), 1–17.
http://dx.doi.org/10.24972/ijts.2007.26.1.1

Mathai, D., Mora, V. & Garcia-Romeu, A. (2022). Toward Synergies of Ketamine and Psychotherapy. Frontiers in Psychology, Vol 13.
https://www.frontiersin.org/articles/10.3389/fpsyg.2022.868103

Wilkinson, S. T., Wright, D., Fasula, M. K., Fenton, L., Griepp, M., Ostroff, R. B., & Sanacora, G. (2017). Cognitive behavior therapy may sustain antidepressant effects of intravenous ketamine in treatment-resistant depression. Psychotherapy and Psychosomatics, 86(3), 162–167. DOI: 10.1159/000457960
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5516265/

YOUNGER & OLDER PATIENTS

Cullen, K. R., Amatya, P., Roback, M. G., Albott, C. S., Westlund Schreiner, M., Ren, Y., … & Reigstad, K. (2018). Intravenous ketamine for adolescents with treatment-resistant depression: an open-label study. Journal of child and adolescent psychopharmacology, 28(7), 437-444. DOI: 10.1089/cap.2018.0030
https://www.ncbi.nlm.nih.gov/pubmed/30004254

Gardner, C. (2017). Case report reveals successful treatment of adolescent depression with ketamine. Yale School of Medicine.
https://medicine.yale.edu/news-article/14682/

George, D., Gálvez, V., Martin, D., Kumar, D., Leyden, J., … & Loo, C. (2017). Pilot Randomized Controlled Trial of Titrated Subcutaneous Ketamine in Older Patients with Treatment-Resistant Depression. The American Journal of Geriatric Psychiatry, 25(7), 1199-1209. DOI: 10.1016/j.jagp.2017.06.007
https://www.sciencedirect.com/science/article/abs/pii/S1064748117303512?via%3Dihub

Papolos, D., Frei, M., Rosssigtnol, D., Mattis, S., Hernandez, L. C. & Teicher, M. H. (2018). Clinical experience using intranasal ketamine in the longitudinal treatment of juvenile bipolar disorder with fear of harm phenotype. Journal of Affective Disorders, 225, 545-551. DOI: 10.1016/j.jad.2017.08.081
https://www.sciencedirect.com/science/article/abs/pii/S0165032717305888

Turban, J. (2017). The ketamine breakthrough for suicidal children. Scientific American.
https://www.scientificamerican.com/article/the-ketamine-breakthrough-for-suicidal-children/

Zarrinnegar, P., Kothari, J., & Cheng, K. (2019). Successful use of ketamine for the treatment of psychotic depression in a teenager. Journal of Child and Adolescent Psychopharmacology, 29(6), 472-473. DOI: 10.1089/cap.2019.0028
https://www.ncbi.nlm.nih.gov/pubmed/31161948

BIPOLAR DISORDER

Bennett, R., Yavorsky, C. & Bravo, G. (2022). Ketamine for bipolar depression: biochemical, psychotherapeutic, and psychedelic approaches. Frontiers in Psychiatry, 13. DOI: 10.3389/fpsyt.2022.867484
https://www.frontiersin.org/articles/10.3389/fpsyt.2022.867484/full

POST-TRAUMATIC STRESS DISORDER

Liriano, F., Hatten, C., & Schwartz, T. L. (2019). Ketamine as treatment for post-traumatic stress disorder: A review. Drugs in context, 8, 212305. DOI: 10.7573/dic.212305
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6457782/

Halstead, M., Reed, S., Krause, R. & Williams, M. (2021). Ketamine-assisted psychotherapy for PTSD related to racial discrimination. Clinical Case Studies, 20(4), 310-330. DOI: 10.1177/1534650121990894
https://journals.sagepub.com/doi/full/10.1177/1534650121990894

Ross, C., Jain, R., Bonnett, C. J., & Wolfson, P. (2019). High-dose ketamine infusion for the treatment of posttraumatic stress disorder in combat veterans. Annals of Clinical Psychiatry, 31(4), 271-279.
https://www.ncbi.nlm.nih.gov/pubmed/31675388

OBSESSIVE-COMPULSIVE DISORDER

Bottemanne, H., & Arnould, A. (2021). Ketamine augmentation of exposure response prevention therapy for obsessive-compulsive disorder. Innovations in clinical neuroscience, 18(10-12), 9–11.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8794478/

Rodriguez, C. I., Kegeles, L. S., Flood, P., & Simpson, H. B. (2011). Rapid resolution of obsessions after an infusion of intravenous ketamine in a patient with treatment-resistant obsessive-compulsive disorder. The Journal of Clinical Psychiatry, 72(4), 567–569. DOI: 10.4088/JCP.10l06653
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3727240/

Rodriguez, C. I., Wheaton, M., Zwerling, J., Steinman, S. A., Sonnenfeld, D., Galfalvy, H., & Simpson, H. (2016). Can exposure-based CBT extend the effects of intravenous ketamine in obsessive-compulsive disorder? An open-label trial. The Journal of Clinical Psychiatry, 77(3), 408–409. DOI: 10.4088/JCP.15l10138
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5544939/

EATING DISORDER

Calabrese, L., Scolnick, B., Zupec-Kania, B., Beckwith, C., Costello, K. & Guido, F. (2022). Ketogenic diet and ketamine infusion treatment to target chronic persistent eating disorder psychopathology in anorexia nervosa: a pilot study. Eating and Weight Disorders. DOI: 10.1007/s40519-022-01455
https://doi.org/10.1007/s40519-022-01455-x

Mills, I. H., Park, G. R., Manara, A. R. & Merriman, R. J. (1998) Treatment of compulsive behaviour in eating disorders with intermittent ketamine infusions. QJM International Journal of Medicine, 91(7), 493-503. DOI: 10.1093/qjmed/91.7.493
https://academic.oup.com/qjmed/article/91/7/493/1598067

Skolnick, B., Zupec-Kania, B., Calabrese, L., Aoki, C. & Hildebrandt, T. (2020). Remission from chronic anorexia nervosa with ketogenic diet and ketamine. Frontiers in Psychiatry. DOI: 10.3389/fpsyt.2020.00763
https://www.frontiersin.org/articles/10.3389/fpsyt.2020.00763/full

SUBSTANCE USE DISORDERS

Dakwar, E., Anerella, C., Hart, C. L., Levin, F. R., Mathew, S. J., & Nunes, E. V. (2014). Therapeutic infusions of ketamine: Do the psychoactive effects matter? Drug and Alcohol Dependence, 136, 153–157. DOI :10.1016/j.drugalcdep.2013.12.019
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4091719/

Dakwar E., Nunes, E.V., Hart, C.L., Hu, M.C., Foltin, R.W., & Levin, F. R. (2018) A sub-set of psychoactive effects may be critical to the behavioral impact of ketamine on cocaine use disorder: Results from a randomized, controlled laboratory study. Neuropharmacology, 142, 270-276. DOI: 10.1016/j.neuropharm.2018.01.005.
https://europepmc.org/article/PMC/6033686

Dakwar, E., Nunes, E. V., Hart, C. L., Foltin, R. W., Mathew, S. J., Carpenter, K. M.,… & Levin, F. R. (2019). A single ketamine infusion combined with     mindfulness-based behavioral modification to treat cocaine dependence: A randomized clinical trial. American Journal of Psychiatry, 176(11), 923-930. DOI: 10.1016/j.neuropharm.2018.01.005
https://doi.org/10.1176/appi.ajp.2019.18101123

Jones, J. L., Mateus, C. F., Malcolm, R. J., Brady, K. T., & Back, S. E. (2018). Efficacy of ketamine in the treatment of substance use disorders: A Systematic Review. Frontiers in psychiatry, 9, 277. DOI: 10.3389/fpsyt.2018.00277
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6094990/

Krupitsky, E., Burakov, A., Romanova, T., Dunaevsky, I., Strassman, R., & Grinenko, A. (2002). Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up. Journal of Substance Abuse Treatment, 23, 273-283. DOI: 10.1016/s0740-5472(02)00275-1
https://www.researchgate.net/publication/10978647_Ketamine_psychotherapy_for_heroin_addiction_Immediate_effects_and_two-year_follow-up

Lalanne, L., Nicot, C., Lang, J. P., Bertschy, G., & Salvat, E. (2016). Experience of the use of ketamine to manage opioid withdrawal in an addicted woman: a case report. BMC Psychiatry, 16(1), 395. DOI: 10.1186/s12888-016-1112-2
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5105239/

Rothberg, R., L., Azhari, N., Haug, N., Dakwar, E. (2020) Mystical-type experiences occasioned by ketamine mediate its impact on at-risk drinking: Results from a randomized, controlled trial. Journal of Psychopharmacology, 12/13/2020. DOI: 10.1177/0269881120970879
https://journals.sagepub.com/doi/abs/10.1177/0269881120970879

SUICIDALITY

Calabrese, L. (2019). Titrated serial ketamine infusions stop outpatient suicidality and avert ER Visits and hospitalizations. International Journal of Psychiatry Research, 2(6), 1-12.
http://scivisionpub.com/pdfs/titrated-serial-ketamine-infusions-stop-outpatient-suicidality-and-avert-er-visits-and-hospitalizations-918.pdf

SIDE EFFECTS & SAFETY PROFILE

Acevedo-Diaz, E.E., Cavanaugh, G.W., Greenstein, D., Kraus, C., Kadriu, B., Zarate, C.A. Jr, & Park, L.T. (2019). Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression. Journal of Affective Disorders.
https://doi.org/10.1016/j.jad.2019.11.028

Andrashko, V., Novak, T., Bunovsky, M., Klirova, M., Sos, P., & Horacek, J. (2020). The antidepressant effect of ketamine is dampened by concomitant benzodiazepine medication. Frontiers in Psychiatry, 08/28/2020. DOI: 10.3389/fpsyt.2020.00844
https://www.frontiersin.org/articles/10.3389/fpsyt.2020.00844/full

Feifel, D., Dadiomov, D., & Lee, K. (2020). ​Safety of repeated administration of parenteral ketamine for depression​. ​Pharmaceuticals 2020​, 13(7);
doi:10.3390/ph13070151

Short, B., Fong, J., Galvez, V., Shelker, W., & Loo, C. K. (2018). Side-effects associated with ketamine use in depression: a systematic review. The Lancet Psychiatry, 5(1), 65-78. DOI: 10.1016/S2215-0366(17)30272-9
http://www.kaimacdonald.com/wp-content/uploads/2018/04/Short-2017-common-side-effects-with-ketamine-for-depression-w.pdf

Singh, J. B. (2019). Elevated blood pressure from Esketamine not major concern. Healio Psychiatry.
https://www.healio.com/psychiatry/depression/news/online/%7B563e1d7d-af5c-4152-9851-4d040a53751e%7D/elevated-blood-pressure-from-esketamine-not-major-concern

ESKETAMINE / SPRAVATO

Anderson, P. (2019). FDA’s rapid approval of Esketamine for severe depression questioned. Medscape.
https://www.medscape.com/viewarticle/921248

Bahji, A., Vazquez, G. H., & Zarate, C. A. (2021). Comparative efficacy of racemic ketamine and esketamine for depression: A systemic review and meta-analysis. Journal of Affective Disorders (278) 542-55.
DOI: https://doi.org/10.1016/j.jad.2020.09.071
https://www.sciencedirect.com/science/article/pii/S016503272032766X

Ramos, M. A., Boyd, W., & Alpert, M. D. (2019). Opinion: The new ketamine-based antidepressant is a rip-off; Johnson & Johnson patented a form of the psychedelic with less research and a ridiculous price tag. VICE.
https://www.vice.com/en_us/article/pajkjy/opinion-the-new-ketamine-based-antidepressant-is-a-rip-off

Ross, E. L. & Soeteman, D. I. (2020). Cost-effectiveness of esketamine nasal spray for patients with treatment-resistant depression in the United States. Psychiatric Services, 2020.
https://ps.psychiatryonline.org/doi/10.1176/appi.ps.201900625

MAIL ORDER KETAMINE

Huet, E. (2022). Online ketamine clinics face tougher times after Covid-era boom. Bloomberg News, 11/14/22.
Bloomberg 11-14-22

Love, S. (2021). Psychedelic telemedicine has arrived… What could possibly go wrong? VICE. 
https://www.vice.com/en/article/pkpp3k/psychedelic-telemedicine-has-arrived-what-could-possibly-go-wrong

Copyright © 2023 · KRIYA Ketamine Research Institute